With the North American cannabis market boasting an estimated worth of $7.2 billion in 2016, and new reports projecting CAGR of between 17 percent and 25 percent within the next few years, it’s certainly an exciting time to invest in the marijuana market.
This inhibition has been a major obstacle for dispensaries and other cannabis-related businesses, but the use of bitcoin technology could be the key to overcoming the roadblock.
ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning provided an update on its construction and expansion timelines for its Vanluven and Kimmett facilities, both of which are located in Napanee, Ontario.
ABcann is new to the public market, having launched its initial public offering on May 4. However, the company is one of the most experienced Canadian growers.
India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of pain and other conditions.
PI has put a “Buy” rating on the stock and set a one-year price target of $2.25, implying a return of well over 100 percent.
India Globalization Capital, Inc. (NYSE MKT: IGC) is a company in transition, now targeting pharmaceutical development in the U.S., while curtailing other businesses such as electronics trading in Hong Kong. IGC long-term plans are to establish and extend its development of phytocannabinoid-based pharmaceutical products to treat diseases such as epilepsy and cachexia.
Now, India Globalization Capital, Inc. (NYSE MKT: IGC) is taking a leaf from the Sony playbook. This pioneering company is a ‘first mover’ in the cannabinoid combination therapy space.
India Globalization Capital, Inc. (NYSE MKT: IGC) is developing disruptive new pharmaceutical therapies to fight a variety of ailments.
Most of the current research and development (R&D) surrounding cannabis revolves around understanding these biologically-active ingredients, especially cannabinoids.
The Bethesda, Maryland-based company is a first mover in “combination therapies” that merge cannabinoids with existing drugs to provide more effective remedies.
According to the study, patients who received CBD treatment exhibited over 45 percent mean reduction in seizures, and researchers were outspoken in support of further research.
ChineseInvestors.com, Inc. (OTCQB: CIIX) is offering a unique opportunity for investors as the company pursues a multi-pronged approach to conquering the rapidly expanding global markets in cannabidiol products and the medical marijuana space in Canada. The company aims to be the world’s leading publicly traded Chinese nutritional company.
CBD has long been considered to have a broad range of medical benefits. Now, two major studies released in the last four months have scientifically validated the medicinal efficacy of CBD.
The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use.
